Analyst Ratings For Concert Pharmaceuticals (NASDAQ:CNCE)
Today, Concert Pharmaceuticals (NASDAQ:CNCE) stock received an upgrade by Mizuho from Neutral to Buy with a price target of $27.00.
Some recent analyst ratings include
- 3/9/2018-Mizuho Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 3/2/2018-HC Wainwright Reiterated Rating of Buy .
- 1/12/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 6/12/2017-Aegis Reiterated Rating of Buy.
- 9/7/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Concert Pharmaceuticals (NASDAQ:CNCE)
Concert Pharmaceuticals (NASDAQ:CNCE) has insider ownership of 10.10% and institutional ownership of 71.74%.
- On 2/1/2018 Richard Aldrich, Director, sold 11,946 with an average share price of $20.89 per share and the total transaction amounting to $249,551.94.
- On 1/29/2018 Richard Aldrich, Director, sold 18,054 with an average share price of $20.63 per share and the total transaction amounting to $372,454.02.
- On 1/26/2018 Richard Aldrich, Director, sold 5,000 with an average share price of $20.46 per share and the total transaction amounting to $102,300.00.
- On 1/24/2018 Richard Aldrich, Director, sold 30,000 with an average share price of $19.68 per share and the total transaction amounting to $590,400.00.
- On 1/22/2018 Richard Aldrich, Director, sold 10,000 with an average share price of $19.55 per share and the total transaction amounting to $195,500.00.
- On 1/19/2018 Richard Aldrich, Director, sold 30,000 with an average share price of $19.35 per share and the total transaction amounting to $580,500.00.
- On 1/16/2018 Richard Aldrich, Director, sold 31,236 with an average share price of $19.14 per share and the total transaction amounting to $597,857.04.
Recent Trading Activity for Concert Pharmaceuticals (NASDAQ:CNCE)
Shares of Concert Pharmaceuticals closed the previous trading session at 25.12 up +3.00 13.56% with shares trading hands.
